Transthyretin amyloidosis (ATTR) is a fatal disease caused by the systemic aggregation and deposition of transthyretin (TTR), a blood transporter that is mainly produced in the liver. TTR deposits are made of elongated amyloid fibrils that interfere with normal tissue function leading to organ failure. The current standard care for hereditary neuropathic ATTR is liver transplantation or stabilization of the native form of TTR by tafamidis. In our previous work, we explored an additional strategy to halt protein aggregation by capping pre-existing TTR fibrils with structure-based designed peptide inhibitors. Our best peptide inhibitor TabFH2 has shown to be effective at inhibiting not only TTR aggregation but also amyloid seeding driven by fibrils extracted from ATTR patients. Here we evaluate the effects of peptide inhibitors in two Drosophila models of neuropathic ATTR and compared their efficacy with diflunisal, a protein stabilizer currently used off-label for the treatment of ATTR. Our peptide inhibitor TabFH2 was found the most effective treatment, which resulted in motor improvement and the reduction of TTR deposition. Our in vivo study shows that inhibiting TTR deposition by peptide inhibitors may represent a therapeutic strategy for halting the progression of ATTR.
Introduction
Transthyretin amyloidosis (ATTR) is caused by the deposition of amyloid fibrils of transthyretin (TTR), a transporter of thyroxine and retinol in the blood and cerebrospinal fluid (Costa et al., 1978; Sletten et al., 1980; Westermark et al., 1990) . Both mutant and/or wild-type TTR are found in these deposits, which are made of elongated, resilient amyloid fibrils. Although TTR deposits in virtually every organ, ATTR patients commonly exhibit progressive cardiomyopathy and/or polyneuropathy that lead to disability and death (Galant et al., 2017) . In hereditary ATTR, deposition and disease progression is accelerated by TTR mutations thereby resulting in earlier onsets (Hurshman Babbes et al., 2008) . The most common form of hereditary amyloidosis, ATTR-V30M, is associated with familial amyloid polyneuropathy (FAP) that typically manifests in the third or forth decade of life, with or without cardiac involvement (Gertz et al., 2015) .
The current standard of care for hereditary ATTR cases is liver transplantation. Because TTR is mainly synthesized in the liver, this procedure replaces the circulating mutated TTR with the more stable wild-type TTR (Benson, 2012) . Liver transplantation has prolonged the life of many ATTR patients, with the most favorable prognosis for FAP-V30M cases (Benson, 2013) . However, this drastic procedure is not recommended for cases of advanced age, longstanding disease, or with cardiac involvement, factors that have been associated with higher post-surgical mortality (Carvalho et al., 2015) . In patients with a significant cardiac involvement, amyloid derived from wild-type TTR produced by the transplanted liver may continue to add to existing cardiac deposits, leading to accelerated deposition and heart failure (Liepnieks and Benson, 2007) . Liver transplantation remains the only specific therapy for a limited number of ATTR patients in many countries.
More recent efforts are focused on the stabilization of the native form of TTR by small compounds as a method to inhibit protein aggregation (Miroy et al., 1996) . The functional native form of TTR is a tetramer made of two homo-dimers that form a hydrophobic tunnel in which thyroxine binds as it is transported (Nilsson et al., 1975) . The aggregation of transthyretin to form amyloid fibrils starts by the dissociation of the tetramer into monomers that unfold to expose amyloidogenic segments (Foss et al., 2005) . Kelly and coworkers found that compounds bound to the thyroxine site stabilize the tetramer, thereby inhibiting protein aggregation (Miroy et al., 1996; Baures et al., 1998) . Out of those studies, a stabilizing compound known as Tafamidis was
